Antibiotic-resistance genes: a clinical guide
What common resistance genes signal, which antibiotic classes they affect, and how to interpret them alongside culture and susceptibility testing.
General medical information for education only, not medical advice. For the genes each InnovexLab panel reports, see the antibiotic-resistance panel. This page is for education and does not replace advice from a clinician.
Common resistance genes
| Gene or family | Mechanism | Antibiotics affected | Clinical note |
|---|---|---|---|
| mecA | Encodes PBP2a, a penicillin-binding protein with low affinity for most beta-lactams. | Methicillin/oxacillin and most beta-lactams (MRSA, methicillin-resistant coagulase-negative staphylococci). | femA is a Staphylococcus aureus marker often reported with mecA to support an S. aureus source. |
| vanA, vanB | Alter the peptidoglycan precursor target (D-Ala-D-Lac). | Vancomycin (vanA: vancomycin and teicoplanin; vanB: vancomycin, teicoplanin usually active). | Characteristic of vancomycin-resistant enterococci (VRE). |
| CTX-M, SHV, TEM | Beta-lactamase gene families. CTX-M enzymes are the most common extended-spectrum beta-lactamases (ESBLs). | Penicillins, cephalosporins including third-generation agents, and aztreonam (ESBL phenotype). | SHV and TEM families include narrow-spectrum variants; detection of the family alone does not confirm an ESBL. |
| AmpC | Cephalosporinase (chromosomal or plasmid-mediated). | Cephamycins (e.g. cefoxitin), third-generation cephalosporins and some beta-lactam/inhibitor combinations. | Cefepime and carbapenems are often less affected; inducible chromosomal AmpC matters in some Enterobacterales. |
| KPC, NDM, VIM, IMP, OXA-48 | Carbapenemases: KPC (class A), NDM/VIM/IMP (class B metallo-beta-lactamases), OXA-48 (class D). | Carbapenems and most other beta-lactams (carbapenem-resistant Enterobacterales, CRE). | The enzyme class affects which newer agents may retain activity; infection-control notification is usually required. |
| qnrA, qnrB | Plasmid-mediated proteins that protect DNA gyrase and topoisomerase IV. | Fluoroquinolones (usually low-level resistance). | Can combine with chromosomal mutations to produce higher-level resistance. |
| ermA, ermB | rRNA methylases that alter the macrolide binding site. | Macrolides, lincosamides (clindamycin) and streptogramin B (MLSB phenotype). | Resistance to clindamycin may be inducible. |
| mefA | Efflux pump. | Macrolides (M phenotype); clindamycin typically unaffected. | |
| PVL | Panton-Valentine leukocidin, a toxin, not a resistance mechanism. | None (virulence factor). | Associated with community-associated S. aureus skin infections and necrotizing pneumonia. |
Interpreting a resistance-gene result
- A gene is a genotype. Expression, and therefore phenotypic resistance, can differ.
- An undetected gene does not prove susceptibility: other mechanisms (porin loss, efflux, target mutations) are not detected.
- In a specimen with more than one organism, a detected gene cannot be assigned to a specific organism.
- A gene family may include variants with different spectra; confirm with culture and susceptibility testing where available.
Sources
- CDC. Antimicrobial Resistance: Threats and data.
- IDSA. Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections.
- CDC. ESBL-producing Enterobacterales.
- CDC. Carbapenem-resistant Enterobacterales (CRE).
- CDC. MRSA.
- CDC. Vancomycin-resistant Enterococci (VRE).
Sources accessed November 2026. Links open external sites that InnovexLab does not control.
Medical disclaimer
This page is general educational information summarized from published public-health and professional-society guidance. It is not medical advice, a diagnosis or a treatment recommendation, and reading it does not create a clinician–patient relationship with InnovexLab. Decisions about testing, diagnosis and treatment belong to the treating clinician, using the patient’s history and examination, laboratory and susceptibility results, local resistance patterns and current guidelines. Guidance changes over time; consult the original sources for the latest version. InnovexLab provides this information as is and does not warrant that it is complete or current.
Patients with questions about their health should contact their own healthcare provider. In an emergency, call 911.